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Cbu Cl estimated in elderly patients was 43.55% with respect to 
younger patients. Besides, the Cbu Cl estimated was 5.69 % higher and 
26.85 % lower than the Cbu Cl calculated using the Calvert equation 
for young and elderly patients groups respectively.
Conclusions: The Cbu Cl calculation by means of Calvert formula 
showed under-estimation of the dose to administer at younger patients 
and upper-estimation of the dose to elderly patients. It is necessary to 
study the covariates which contribute to take away the strength of the 
Calvert equation, because affect the efﬁcacy and toxicity of Carbopla-
tin. 
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Background: The clinical beneﬁt of non-cisplatin doublets vs a single 
agent in elderly or unﬁt p is still controversial. The present study 
focuses on clinical outcome with VRL/GEM in elderly p and the role 
of functional status and comorbidities. Genetic predictive markers of 
response to VRL/GEM will also be examined in genomic and cDNA 
from tumor and circulating tumor DNA.
Methods: 145 chemonaive p with stage IIIB (pleural effusion or 
supraclavicular lymph nodes)-IV or recurrent NSCLC and age > 70 
years were accrued at 32 sites between April 2004 and January 2006. 
Treatment consisted of VRL 25 mg/m2 IV or 60-80 mg/m2 oral plus 
GEM 1200 mg/m2, days 1, 8 every 21 days. Activities of daily living 
(ADL), instrumental activities of daily living (IADL) and comorbidi-
ties were evaluated. DNA samples were collected from primary tumors 
for the assessment of microtubule associated protein 4 (MAP4) and 
from serum for the checkpoint with forkhead-associated and ring ﬁnger 
(CHFR) methylation.
Results: Data on 130 p is available for toxicity and 95 for response. 
Median age 76 years (69-83); males: 86.8%; smokers: 70.5%; PS 0-1: 
83.9%; adenocarcinoma: 34.4% / squamous: 48%; stage IIIB: 22.7%, 
IV: 77.3%. Self-sufﬁciency in ADL and IADL was 77.4% and 45.2% 
of the p analyzed. 68% of the p had comorbidities. Median cycles: 3 
(1-8). 461 cycles were performed, 16.3% were delayed and 2.1% had 
dose reduction. Hematological toxicities (%p): grade 3/4 neutropenia, 
7.8%/4.7%; grade 3/4 thrombocytopenia, 2.3%/0.8%; grade 3 anemia, 
3.1%. Efﬁcacy in evaluable population: PR, 23.2% (95% CI, 15.1% to 
32.9%); SD, 41.1%. 24 p died during the treatment period (non toxicity 
related) and 21 p were not evaluable. With a median follow up of 5.8 
months, median survival for the whole population was 4.97 months 
(m), progression free survival 4.53 m, event free survival 3.43 m, 1-
year survival 26.6%. Statistically signiﬁcant differences in median sur-
vival were observed among subgroups: PS 0-1/2, 6.5/2.3 m (p<0.001); 
sex male/female, 4.5/9.7 m (p 0.027); ADL <6/=6, 3.4/7.1 m (p 0.023).
Conclusions: This trial conﬁrms that VRL/GEM is effective, present-
ing a favourable response/toxicity ratio in elderly p with advanced 
NSCLC. Complete data on genetic markers will be presented. 
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Background: Recent experimental studies have suggested that chronic 
administration of comparatively low doses of cytotoxic drugs at close, 
regular intervals, with no prolonged drug-free interruptions, known as 
“metronomic chemotherapy”, may target tumor-associated endothelial 
cells and can induce clinical meaningful effect in selected patients with 
solid tumors. 
Purpose: We report initial results of compassionate use of metronomic 
cyclophosphamide (50 mg p.o. daily until clinical disease progres-
sion or any grade 3-4 toxicity) in patients with advanced or metastatic 
lung cancer pre-treated with at least one platinum-based regimen and 
deemed unﬁt to further cytotoxic therapy.
Results: Data on sixteen patients enrolled between January 2005 and 
June 2006 are evaluable: most had a Karnofsky performance status of 
70% (10 pts), metastatic disease (9 pts), and 14 were pre-treated with 
a cisplatin/vinorelbine regimen; 15 had progressive disease at study 
entry, and 9 had progressive disease during the last therapy. One patient 
interrupted treatment due to recurrent grade-2 bladder hemorrhage. We 
noticed 2 partial remission (PR) (12%, 95% CI 0-28%) and 9 stable 
disease (SD) (56%, 95% CI 32-80%); the clinical beneﬁt rate (PR 
plus SD for > or = 24 weeks) in all pts were 44% (95% CI, 19-68%). 
Median survival was 11.9 months (95% CI 2.3-21.5 mo.) and 1-year 
survival rate was 47.7%. 
Conclusion: Metronomic cyclophosphamide chemotherapy is effective 
and minimally toxic in pre-treated lung cancer patients. 
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Background: Along with an acceptable tolerability proﬁle, single 
agent oral vinorelbine has shown to be effective in elderly NSCLC 
p. The oral formulation avoids the side effects associated with the IV 
injection, may reduce administration and toxicity-related costs and is 
easy to administer. Due to these advantages, single agent oral vinorel-
